Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $287.40 million
- Book Value:
- Revenue TTM:
- $177.45 million
- Operating Margin TTM:
- Gross Profit TTM:
- $126.52 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Zynex Inc had its IPO on 2002-12-31 under the ticker symbol ZYXI.
The company operates in the Healthcare sector and Medical Distribution industry. Zynex Inc has a staff strength of 900 employees.
Shares of Zynex Inc opened at $8 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $8 - $8.48, and closed at $8.1.
This is a +1.25% increase from the previous day's closing price.
A total volume of 830,376 shares were traded at the close of the day’s session.
In the last one week, shares of Zynex Inc have increased by +7.28%.
Zynex Inc's Key Ratios
Zynex Inc has a market cap of $287.40 million, indicating a price to book ratio of 7.8787 and a price to sales ratio of 3.5664.
In the last 12-months Zynex Inc’s revenue was $177.45 million with a gross profit of $126.52 million and an EBITDA of $23.24 million. The EBITDA ratio measures Zynex Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Zynex Inc’s operating margin was 11.08% while its return on assets stood at 9.03% with a return of equity of 26.28%.
In Q2, Zynex Inc’s quarterly earnings growth was a positive 12.5% while revenue growth was a positive 22.3%.
Zynex Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.47 per share while it has a forward price to earnings multiple of 26.178 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zynex Inc’s profitability.
Zynex Inc stock is trading at a EV to sales ratio of 3.4679 and a EV to EBITDA ratio of 19.0225. Its price to sales ratio in the trailing 12-months stood at 3.5664.
Zynex Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $152.57 million
- Total Liabilities
- $14.10 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Zynex Inc ended 2023 with $152.57 million in total assets and $0 in total liabilities. Its intangible assets were valued at $152.57 million while shareholder equity stood at $62.27 million.
Zynex Inc ended 2023 with $0 in deferred long-term liabilities, $14.10 million in other current liabilities, 36000.00 in common stock, $21.97 million in retained earnings and $20.40 million in goodwill. Its cash balance stood at $58.75 million and cash and short-term investments were $58.75 million. The company’s total short-term debt was $2,043,000 while long-term debt stood at $57.16 million.
Zynex Inc’s total current assets stands at $107.56 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $32.96 million compared to accounts payable of $5.93 million and inventory worth $14.33 million.
In 2023, Zynex Inc's operating cash flow was $-210000.00 while its capital expenditure stood at $210000.
Comparatively, Zynex Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Zynex Inc stock is currently trading at $8.1 per share. It touched a 52-week high of $17.25 and a 52-week low of $17.25. Analysts tracking the stock have a 12-month average target price of $24.
Its 50-day moving average was $8.4 and 200-day moving average was $11.15 The short ratio stood at 19.73 indicating a short percent outstanding of 0%.
Around 4384.7% of the company’s stock are held by insiders while 3305.3% are held by institutions.
Frequently Asked Questions About Zynex Inc
Similar Industry Stocks (Medical Distribution)
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.